GlassScriptPhysician profile
Tony Juneja
NPI 1871519215
$1,003.02
in general payments reported to CMS, 2019-2025
14 companies · $213 in 2025
The $213 reported for 2025 was more than what a typical Addiction Psychiatry provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.08 · 2021: $57.13 · 2022: $254 · 2023: $319 · 2024: $108 · 2025: $213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $640.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $201.10 | 2022-2024 | Invega Sustenna |
| Galderma Laboratories, L.P. | $142.56 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $135.79 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Indivior INC. | $96.08 | 2021-2024 | Sublocade |
| Abbvie INC. | $88.66 | 2022-2023 | |
| Alkermes, INC. | $85.04 | 2019-2024 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $67.59 | 2019-2025 | Rexulti |
| Brainsway USA INC | $45.24 | 2023 | |
| Neurocrine Biosciences, INC. | $39.33 | 2024 | Ingrezza |
| Corium, LLC | $33.75 | 2022-2023 | Azstarys |
| Vanda Pharmaceuticals INC. | $28.36 | 2019 | |
| Almatica Pharma LLC | $14.40 | 2025 | Loreev Xr |
| Braeburn INC. | $13.48 | 2023 | Brixadi |
| Orexo US, INC. | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tony Juneja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.